Fibroblast Growth Factor 23 Independently Predicts Adverse Outcomes After an Acute Coronary Syndrome
Authors' conclusion
FGF23 and other components of MM are independent predictors of HF and death after an ACS. This effect is homogeneous across different subgroups of population, and it is not limited to patients with chronic kidney disease.
Study context
- Population
- Patients at discharge from an acute coronary syndrome (ACS)
- Participants
- 1,190 patients
- Outcome
- Combination of acute ischaemic events, HF and death
- Follow-up
- Median 5.44 (3.03-7.46) years
Methodological detailsmultivariable analysis, Age 61.7 ± 12.2 years; 77.1% men
- Multivariable analysis
- Age 61.7 ± 12.2 years; 77.1% men
Main finding
As reported in the abstract
Independent predictors of the primary outcome (multivariable analysis)
Primary outcome events
294
FGF23, HR
1.18
1.08–1.29P < 0.001
Calcidiol, HR
0.86
0.74–1.00P = 0.046
Observational data: associations, not effects.
Secondary outcomes
Heart failure (HF)
- FGF23, HR
- 1.45 [1.28-1.65], P < 0.001
- Parathormone, HR
- 1.06 1.01-1.12]; P = 0.032
Death
- FGF23, HR
- 1.21 [1.07-1.37], P = 0.002
- Calcidiol, HR
- 0.72 [0.54-0.97), P = 0.028
Acute ischaemic events
- No biomarker predicted acute ischaemic events
Primary outcome, eGFR > 60 mL/min/1.73 m² (subgroup)
- FGF23 independently predicted the primary outcome
Original publication
Fibroblast Growth Factor 23 Independently Predicts Adverse Outcomes After an Acute Coronary Syndrome. ESC Heart Fail. Published 10 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →